News & Updates

In the management of women with polycystic ovary syndrome (PCOS), metformin at various therapeutic doses appears to reduce body weight, body mass index, and waist circumference when compared with placebo, sitagliptin, and acarbose, according to the results of a meta-analysis. On the other hand, pioglitazone and rosiglitazone contribute to an increase in all three outcomes.

At a dose of 6 mg, brolucizumab yields substantial visual gains and anatomical improvements in patients with diabetic macular oedema without increasing the risk of serious adverse ocular events when compared with aflibercept, according to data from two phase III trials.

Acid suppression therapy appears to exert no meaningful effect on the efficacy or safety of plecanatide when administered concomitantly, according to a study.

The first-in-class sphingosine-1-phosphate receptor modulator ozanimod showed promising efficacy and safety in a relatively treatment-refractory cohort of patients with ulcerative colitis (UC), according to the initial results of a prospective, observational cohort study presented at the Crohn’s and Colitis Congress 2022.

While a fourth dose of the COVID-19 vaccine boosts antibodies to levels that are higher than the third dose, it is not enough to protect against Omicron infections, according to preliminary data from Israel.

Treatment with a single-pill combination (SPC) drug, composed of olmesartan and amlodipine, plus a separate dose of rosuvastatin led to significantly reduced systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) levels in patients with concomitant hypertension and dyslipidaemia, according to the LEISURE* trial.

Treatment with dronedarone following atrial fibrillation (AF) ablation appears to lead to a reduced risk of cardiovascular hospitalization as well as lower rates of combined proarrhythmia when compared with sotalol, as shown in a recent study.